Evaluation Joint Effect of 308 nm Excimer Light and Secukinumab on IL-1 and IL-1 RA of Psoriasis Patients Based on Generalized Estimating Equations
Objective To evaluate the joint effect of 308nm excimer light and secukinumab on the aesthetic observation of psoriasis(PS)and the effect on the interleukin-1(IL-1)and IL-1 receptor antagonist(IL-1RA)of psoriasis patients based on generalized estimating equations(GEE).Methods The clinical data of the PS patients(n=120)treated between Jun.2021 and Oct.2023 were retrospective analyzed,and the patients were divided into a treatment group(n=64)and a control group(n=56)by treating methods.The patients in the treatment group were given combined treatment of 308 nm excimer light and secukinumab,and those in the control group only given the treatment of secukinumab.The clinical data of the patients of both groups were collected and compared for analysis.One month and two months after the treatment,GEE was used to evaluate the improvement of IL-1、IL-1RA and area and psoriasis severity index(PASI)respectively for the patients of both groups.Results One month and two months after the treatment,compared with those in the control group,the patients in the treatment group had lower PASI scores and lower levels of IL-1,IL-17,tumor necrosis factor-α(TNF-α)and vascular endothelial growth factor(VEGF)and higher IL-1RA levels(P<0.05).Two months after the treatment,compared with those in the control group,the patients in the treatment group had lower DLQD scores,skin itching levels,adverse reactions(ARS)incurrence and recurrence rates(P<0.05)and higher overall clinical efficacy(P<0.05).The GEE analysis results showed that the improvement of IL-1,IL-1RA and PASI in the treatment group was greater than that in the control group(P<0.05).Conclusions Being a safe,reliable and effective treatment for psoriasis,the combination of 308 nm excimer light and secukinumab will effectively alleviate patients'clinical symptoms,reduce skin lesion areas,alleviate inflammatory reactions,improve patients'quality of life and reduce the incidence of ARS and recurrence of psoriasis.